Zmyra is a non-prescription supplement crafted to support weight loss through appetite suppression, metabolism enhancement, ...

The Loan has minimum fixed interest of $400,000 for the first six months and bears interest at 14.25% per annum thereafter. The Loan principal is due on the Maturity Date, and interest is due and ...

Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of Chris M. Storgard, ...

(Nasdaq: LFMD), a leading provider of virtual primary care services, today announced expanded acceptance of insurance to Medicare beneficiaries for qualifying care. Initially available to more than 21 ...

Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announces the publication of ...

The Ozempic 6 week belly weight reduction program is an effective way to shed those unwanted pounds and promote your overall ...

Verano’s active operations span 13 states, comprised of 155 dispensaries and 15 cultivation and processing facilities with more than 1.1 million square feet of cultivation capacity ...

AMT Medical B.V., a clinical-stage medtech innovator, today announced a $25 million Series B financing round led by Bender Analytical Holding B.V. (BAH). New investors Invest-NL, and the European ...

PHILADELPHIA, April 17, 2025 (GLOBE NEWSWIRE) -- Interius BioTherapeutics, a clinical-stage company engineering targeted, programmable vectors for the precision delivery of genetic medicines, today ...

Christian Boehringer, since 2007 Chairman of the Shareholders’ Committee, has decided to step down from his role with effect from June 30, 2025. The Shareholders’ Committee has appointed Hubertus von ...

ZUG, Switzerland, April 17, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro ...

Ligand Pharmaceuticals Incorporated (“Ligand”) (Nasdaq: LGND) and Channel Therapeutics Corporation (“Channel”) (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment ...